CD20 antibodies: Doing the time warp

Blood

Volumn 118, Issue 2, 2011, Pages 219-220

  Cragg, Mark S ^a  

^a Tenovus Research Laboratory   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE N PROLINE; B LYMPHOCYTE RECEPTOR; CD20 ANTIGEN; COMPLEMENT COMPONENT C1Q; EPITOPE; FC RECEPTOR IIB; INTERLEUKIN 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; OBINUTUZUMAB; OFATUMUMAB; PEPTIDE; PROTEIN; RITUXIMAB; TOSITUMUMAB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; B CELL LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL DEATH; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFOCAL MICROSCOPY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; HUMAN; LYSOSOME; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MOTIF; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

EID: 79960475243     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-346700     Document Type: Note

References (8)

1. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95(1):135-143.
2. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358-367.
3. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107-114.
4. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519- 4529.
5. Ivanov A, Beers SA, Walshe CA, et al. Homotypic adhesion and lysosome-mediated cell death evoked by anti-CD20 (Tositumomab) andHLADRmonoclonal antibodies. J Clin Invest. 2009;119(8):2143-2159.
6. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450-454. (Pubitemid 24272191)
7. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood. 2002;99(9):3256-3262. (Pubitemid 34525305)
8. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371.